Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27526570 | 0.90 | GBA1 (0.45) | GBA1SLC6A4SLC6A2SLC6A3DPP4 | |
| SCHEMBL17604782 | 0.88 | ANPEP (0.46) | ANPEPERAP1ERAP2 | |
| SCHEMBL7785415 | 0.84 | SLC18A2 (0.46) | ANPEPERAP1ERAP2 | |
| SCHEMBL9390743 | 0.84 | ALDH1A1 (0.44) | SLC6A4SLC6A2SLC6A3ANPEPERAP1 | |
| SCHEMBL6551164 | 0.84 | SLC18A2 (0.46) | ANPEPERAP1ERAP2 | |
| SCHEMBL3598731 | 0.84 | DPP4 (0.40) | SLC6A4SLC6A2SLC6A3DPP4 | |
| SCHEMBL27478385 | 0.83 | DPP4 (0.51) | GBA1SLC6A4SLC6A2SLC6A3DPP4 | |
| Hydrochloric Acid SCHEMBL6551559 | 0.83 | SLC18A2 (0.45) | ANPEPERAP1ERAP2 | |
| SCHEMBL3577446 | 0.80 | SLC6A2 (0.43) | GBA1SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL3590306 | 0.80 | TDP1 (0.46) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480892-A | SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5356906-A | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993022310-A1 | (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |